GlassScriptPhysician profile
David M Doriguzzi
NPI 1730195728
$165,568.23
in general payments reported to CMS, 2019-2025
42 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2021: $20K · 2022: $28K · 2023: $31K · 2024: $32K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $36K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $35K · Travel and Lodging: $18K · Food and Beverage: $14K · Consulting Fee: $8,669 · Honoraria: $5,600 · Education: $358 · Gift: $59.40 · Other payment types: $54.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,780.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $34,843.00 |
| Travel and Lodging | $17,813.94 |
| Food and Beverage | $13,807.93 |
| Consulting Fee | $8,668.75 |
| Honoraria | $5,600.00 |
| Education | $357.67 |
| Gift | $59.40 |
| Other payment types | $54.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $74,154.76 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $47,970.90 | 2021-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Corcept Therapeutics | $24,722.64 | 2021-2025 | Korlym |
| Bayer Healthcare Pharmaceuticals INC. | $5,676.49 | 2021-2025 | |
| Mannkind Corporation | $4,202.94 | 2021-2025 | Afrezza |
| Ascensia Diabetes Care US INC. | $1,575.11 | 2023 | |
| Xeris Pharmaceuticals, INC. | $1,146.73 | 2021-2025 | Recorlev, Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $899.30 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Amgen INC. | $792.29 | 2022-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $623.54 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $552.38 | 2021-2025 | Freestyle Libre 3, Freestyle Copilot |
| Astrazeneca Pharmaceuticals LP | $382.98 | 2021-2025 | Farxiga |
| Regeneron Healthcare Solutions, INC. | $355.62 | 2024-2025 | Dupixent |
| Abbvie INC. | $245.49 | 2021-2023 | |
| Pfizer INC. | $211.31 | 2021-2024 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Beta Bionics, INC. | $195.21 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Tandem Diabetes Care, INC. | $174.56 | 2022-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Radius Health, INC. | $159.43 | 2023-2025 | |
| Horizon Therapeutics Plc | $149.90 | 2022-2023 | Tepezza |
| Sanofi-Aventis U.S. LLC | $149.81 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $146.42 | 2021-2023 | Verquvo, Belsomra |
| Medtronic, INC. | $140.06 | 2021-2025 | Minimed 780g |
| Irhythm Technologies, INC. | $134.70 | 2023 | Zio Xt Patch |
| Genzyme Corporation | $124.99 | 2024 | |
| Novartis Pharmaceuticals Corporation | $93.04 | 2022-2023 | |
| Esperion Therapeutics, INC. | $69.55 | 2023-2025 | Nexletol |
| Kyowa Kirin, INC. | $64.69 | 2023-2025 | Crysvita |
| Insulet Corporation | $63.60 | 2022-2025 | Omnipod |
| Sequel Med Tech, LLC | $44.09 | 2025 | Twiist |
| Amarin Pharma, INC. | $41.36 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $35.52 | 2021 | |
| Recordati_rare_diseases_inc. | $34.53 | 2025 | Isturisa |
| Madrigal Pharmaceuticals | $34.03 | 2025 | Rezdiffra |
| Stryker Corporation | $33.17 | 2024 | Insignia |
| Zealand Pharma US, INC. | $30.72 | 2022 | |
| Glaxosmithkline, LLC. | $25.55 | 2025 | Shingrix, Arexvy |
| Lexicon Pharmaceuticals, INC. | $24.23 | 2023 | Inpefa |
| Ascendis Pharma Endocrinology INC | $23.68 | 2025 | Yorvipath |
| Arbor Pharmaceuticals, INC. | $22.80 | 2021 | |
| Astellas Pharma US INC | $21.18 | 2024 | Veozah |
| Exact Sciences Corporation | $18.93 | 2024 | Cologuard Collection Kit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,882.60 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Doriguzzi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.